Kolon TissueGene (950160) Q2 2025 earnings summary

Executive summary

• Focus on cell and gene therapy development, with TG-C as the lead product for osteoarthritis, currently in US Phase 3 clinical trials and additional indications in pipeline (hip OA, DDD).

• Operates a secondary health & beauty distribution business in Korea.

• Significant R&D investment, with 27 research staff and extensive patent portfolio (70 registered, 76 pending).

• Multiple licensing and manufacturing agreements, especially with Kolon Life Science for Asia/Middle East rights.

Financial highlights

• 2025 H1 revenue: $1.83M (down from $3.72M in 2024 H1); operating loss: $(7.61)M.

• Net loss for 2025 H1: $(44.21)M; EPS: $(2.72).

• Cash and equivalents at period end: $10.03M; total assets: $205.3M.

• R&D expenses: $37.94M (2,075% of sales); accumulated deficit: $(344.6)M.

• Equity raised via multiple capital increases and convertible bonds; recent capital stock: $2,808.

Outlook and guidance

• Plans to file for FDA BLA after 2-year follow-up of 1,066 Phase 3 patients.

• Pipeline expansion into hip OA (Phase 2 approved) and DDD (Phase 1 approved); long-term plans for rheumatoid arthritis and animal health.

• Ongoing efforts to secure global partnerships for commercialization outside Asia.